[1]
|
Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., et al. (2001) The sequence of the human genome. Science, 291, 1304-1351. doi:10.1126/science.1058040
|
[2]
|
Law, P.K. (1992) Myoblast transplantation. Science, 257, 1329-1330. doi:10.1126/science.1529326
|
[3]
|
Law, P.K., Bertorini, T., Goodwin, T.G., Chen, M., Fang, Q.W., Li, H.J., et al. (1990) Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy. Lancet, 336, 114-115.doi:10.1016/0140-6736(90)91628-N
|
[4]
|
Law, P.K. (1999) Myoblast transfer as a platform technology for gene therapy. Regulatory Affairs Focus (Technology), 4, 25-27.
|
[5]
|
Law, P.K., Goodwin, T.G., Fang, Q., Vastagh, G., Jordan, T., Jackson, T., et al. (1998) Myoblast transfer as a platform technology of gene therapy. Gene Therapy and Molecular Biology, 1, 345-363.
|
[6]
|
Law, P.K. and Goodwin, T.G. (1992) Compositions for and methods of treating muscle degeneration and weakness. US5130141.
|
[7]
|
Law, P.K. Myoblast therapy for mammalian diseases. EP1407788 (2004), DEP2116DE01, FRP2116FR01, GBP2116GB01, IEP2116IE01, AU748997 (2002), CNZL95192528 (2003), WO9618303 (1996).
|
[8]
|
Law, P.K. (2002) Cardiomyocytes for heart muscles damaged in heart attacks. US020031501.
|
[9]
|
Law, P.K. Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities. US7166279 (2007), DE69815230T2 (2004), IE0898967 (2003), HK1016897 (2004), ME226489 (2005), EP 0898967 (1999).
|
[10]
|
Mickle, D.A., Donald, A.G., Li, R.K. and Weisel, R.D. Transplants for myocardial scars and method and cellular preparations thereof. US6579523 (2003), US2004007- 1669 (2004), US20050025749 (2005), US7067121 (2006), EP0985028 (2006), EP1690546 (2006), US2008- 0159997 (2008), US6099832 (2000).
|
[11]
|
Law, P.K. Cellular transplantation for heart regeneration. US030232431 (2003), WO03085092 (2004), WO0308- 5092 (2004), US20050244384 (2005), WO03085092 (2003).
|
[12]
|
Law, P.K. (2004) Methods for producing cardiomyocytes capable of proliferation. SI99846.
|
[13]
|
Law, P.K. (2001) Automated cell processor. US6261832.
|
[14]
|
Law, P.K. (2001) Instrument for cell culture. SI74036.
|
[15]
|
Law, P.K. Myogenic cell transfer catheter and method. WO0228470 (2002), SI95355 (2005), EP1324802 (2006), AU02211230 (2007), US60231880 (pending).
|
[16]
|
Law, P.K. (2004) Mechanisms of myoblast transfer in treating heart failure. WO2004014302, CN03824045.9 (pending), US60402050 (pending).
|
[17]
|
Jean-Thomas, V., Jean-Pierre, M., Jacques, T., Isabelle, R. and Brigitte, T. (2004) Method for obtaining character-ized muscle-derived cell populations and uses. US2004- 00430 08.
|
[18]
|
Law, P.K. (2005) Myoblast treatment of diseased or weakened organs. WO2005020916.
|
[19]
|
Douglas, B.A. and Dinsmore, J.H. (2006) Catheter-based delivery of skeletal myoblasts to the myocardium of dam-aged hearts. US20060263338.
|
[20]
|
Dinsmore, J.H. (2006) Cellular cardiomyoplasty as supportive therapy in patients with heart disease. US2006-0276685.
|
[21]
|
Dinsmore, J.H. (2007) Treatment for heart disease. US 20070059288.
|
[22]
|
Dinsmore, J.H., Jonathan, H.D. and Harout, D. (2004) Improved injection system. WO04012791
|
[23]
|
Piero, A. Methods and compositions for the repair and/or regeneration of damaged myocardium. WO2007100530 (2006), US7547674 (2009).
|
[24]
|
Law, P.K. Myoblast therapy for cosmetic treatment. US7341719 (2008), SI99279 (2004), CN03101588 (2003).
|
[25]
|
Law, P.K. Biologic skin repair and enhancement. WO- 017972(2004), CN03819963 (2008), SI110581 (2007).
|
[26]
|
Beardsley, T. (1990) Profile: Gene doctor. W. French Anderson pioneers gene therapy. Scientific American, 263, 33-34. doi:10.1038/scientificamerican1290-33
|
[27]
|
Anderson, W.F. (1990) The beginning. Human Gene The- rapy, 1, 371-372. doi:10.1089/hum.1990.1.4-371
|
[28]
|
Culver, K.W., Osborne, W.R., Miller, A.D., Fleisher, T.A., Berger, M., Anderson, W.F., et al. (1991) Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. Transplantation Proceedings, 23, 170-171.
|
[29]
|
Anderson, W.F. (1992) Human gene therapy. Science, 256, 808-813. doi:10.1126/science.1589762
|
[30]
|
Law, P.K., Goodwin, T.G., Fang, Q., Deering, M.B., Dug-girala, V., Larkin, C., et al. (1993) Cell transplantation as an experimental treatment for Duchenne muscular dys-trophy. Cell Transplant, 2, 485-505.
|
[31]
|
Law, P.K. (1994) Myoblast Transfer: Gene therapy for muscular dystrophy. RG Landes Company, Austin, 139- 154.
|
[32]
|
Law, P.K., Goodwin, T.G., Fang, Q., Quinley, T., Vastagh, G., Hall, T., et al. (1997) Human gene therapy with myo- blast transfer. Transplantation Proceedings, 29, 2234- 2237. doi:10.1016/S0041-1345(97)00312-6
|
[33]
|
Gussoni, E., Pavlath, G.K., Lanctot, A.M., Sharma, K.R., Miller, R.G., Steinman, L., et al. (1992) Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature, 356, 435-438. doi:10.1038/356435a0
|
[34]
|
Tremblay, J.P., Malouin, F., Roy, R., Huard, J., Bouchard, J.P., Satoh, A., et al. (1993) Results of a triple blind clini-cal study of myoblast transplantations without immuno-suppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant, 2, 99-112.
|
[35]
|
Huard, J., Bourchard, J.P., Roy, R., Labrecque, C., Dan-sereau, G., Lemieux, B., et al. (1991) Myoblast transplantation produced dystrophinpositive muscle fibers in a 16-year-old patient with Duchenne muscular dystrophy. Clinical Science, 81, 287-288.
|
[36]
|
Law, P.K., Goodwin, T.G., Fang, Q., Hall, T.L., Quinley, T., Vastagh, G., et al. (1997) First human myoblast trans-fer therapy continues to show dystrophin after 6 years. Cell Transplant, 6, 95-100. doi:10.1016/S0963-6897(96)00138-8
|
[37]
|
Law, P.K., Haider, K., Fang, G., Jiang, S., Chua, F., Lim, Y.T., et al. (2002) Mechanisms of myoblast transfer in treating heart failure. In: Kimchi, A., Ed., Advances in Heart Failure, Medimont, 43-48.
|
[38]
|
Law, P.K. (2002) The regenerative heart. Business briefing, Pharmtech, 65-71.
|
[39]
|
Law, P.K., Haider, K., Fang, G., Jiang, S., Chua, F., Lim, Y.T., et al. (2004) Human VEGF165-myoblasts produce concomitant angiogenesis/myogenesis in the regenerative heart. Molecular and Cellular Biochemistry, 263, 173-178. doi:10.1023/B:MCBI.0000041859.60354.f5
|
[40]
|
Law, P.K., Sim, E.K.W., Haider, K.H., Feng, G., Chua, F., Kakuchaya, T., et al. (2004) Myoblast genome therapy and the regenerative heart. In: Kipshidze, N.N. and Serruys, P.W., Eds., Handbook of Cardiovascular Cell Transplantation, Dunitz Ltd, London, 241-257.
|
[41]
|
Ye, L., Haider, H.Kh., Jiang, S., Ge, R, Law, P.K., Sim E.K. (2005) In vitro functional assessment of human skeletal myoblasts after transduction with adenoviral bicistronic vector carrying human VEGF165 and angiopoietin-1. The Journal of Heart and Lung Transplantation, 24, 1393-1402.
|
[42]
|
Law, P.K., Weinstein, J., Ben Hain, S., Williams, S., Fang, Q., Hall, T., et al. (2000) World’s first human myoblast transfer into the heart. Front Physiol, A85.
|
[43]
|
Law, P.K., Weinstein, J., Ben Hain S, Williams, S., Fang, Q., Hall, T., et al. (2000) World’s first human myoblast transfer into the heart. Acta Physiol Scand, 170, A17.
|
[44]
|
Law, P.K. (2001) Nuclear transfer and human genome therapy. Business Briefing Future Drug Discovery (Genomics), 38-42.
|
[45]
|
Haider, H.K.H., Jiang, S.J., Ye, L., Aziz, S., Law, P.K., Sim, E.K. (2004) Effectiveness of transient immunosuppression using cyclosporine for xenomyoblast transplantation for cardiac repair. Transplantation Proceedings, 36, 232-235. doi:10.1016/j.transproceed.2003.11.001
|
[46]
|
Law, P.K., Goodwin, T.G., Fang, Q., Duggirala, V., Larkin, C., Florendo, J.A., et al. (1992) Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscu-lar dystrophy boys. Cell Transplant, 1, 235-244.
|
[47]
|
Law, P.K., Leo, A.B., Lu, P., Liew, C.-C., Law, D.M., Sim, E.K.W., et al. (2006) Human myoblast genome therapy. Journal of Geriatric Cardiology, 3, 135-151.
|
[48]
|
Ye, L., Husnain, H., Jiang, S. and Eugene, S. (2004) Therapeutic angiogenesis. Basic Research in Cardiology, 99, 121-132.
|
[49]
|
Ferrara, N. (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. American Journal of Physiology, 280, C1358-66.
|
[50]
|
Shibuya, M., Ito, N. and Claesson-Welsh, L. (1999) Struc- ture and function of vascularendothelial growth factor receptor-1 and -2. Current topics and functional restora-tion. European Heart Journal, 24, 404-411.
|
[51]
|
Freedman, S.B. and Isner, J.M. (2002) Therapeutic angiogenesis for coronary artery disease. Annals of Internal Medicine Journal, 136, 54-71.
|
[52]
|
Hockel, M., Schlenger, K., Doctrow, S., Kissel, T. and Vaupel, P. (1993) Therapeutic angiogenesis. Archives of Surgery, 128, 423-429. doi:10.1001/archsurg.1993.01420160061009
|
[53]
|
Haider, H.K.H., Ye, L., Jiang, S., Ge, R., Law, P.K. and Chua, T., et al. (2004) Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. Journal of Molecular Medicine, 82, 539-549. doi:10.1007/s00109-004-0546-z
|
[54]
|
Ye, L., Haider, H.K.H., Tan, R.S., Toh, W.C.H., Law, P.K., Tan, W.B., et al. (2007) Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation, 116, I-113-20. doi:10.1161/CIRCULATIONAHA.106.680124
|
[55]
|
Ye, L., Haider, H.K.H., Tan, R., Su, L., Law, P.K., Zhang, W, et al. (2008) Angiomyogenesis using liposome based vascular endothelial growth factor-165 transfection with skeletal myoblast for cardiac repair. Biomaterials, 29, 2125-2137. doi:10.1016/j.biomaterials.2008.01.014
|
[56]
|
Ye, L., Haider, H.K.H., Jiang, S.J., Ling, L.H., Ge, R.W., Law, P.K. and Sim, E.K.W. (2005) Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model. The European Journal of Heart Failure, 7, 945-952. doi:10.1016/j.ejheart.2005.03.012
|
[57]
|
Su, H., Lu, R. and Kan, Y.W. (2000) Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proceedings of the National Academy of Sciences, 97, 13801-13806. doi:10.1073/pnas.250488097
|
[58]
|
Lee, R.J. and Springer, M.L., Blanco-Bose, W.E., Shaw, R., Ursell, P.C., Blau, H.M. (2000) VEGF gene delivery to myocardium: Deleterious effects of unregulated ex-pression. Circulation, 102, 898-901. doi:10.1161/01.CIR.102.8.898
|
[59]
|
Lehrman, S. (1999) Virus treatment questioned after gene therapy death. Nature, 401, 517-518. doi:10.1038/43977
|
[60]
|
Liu, Q. and Muruve, D.A. (2003) Molecular basis of the inflammatory response to adenovirus vectors. Gene Therapy, 10, 935-940. doi:10.1038/sj.gt.3302036
|
[61]
|
Marshall, E. (2000) Gene therapy death prompts review of adenovirus vector. Science, 286, 2244-2245. doi:10.1126/science.286.5448.2244
|
[62]
|
Sun, J.Y., Anand-Jawa, V., Chatterjee, S. and Wong, K.K. (2003) Immune responses to adeno-associated virus and its recombinant vectors. Gene Therapy, 10, 964-976. doi:10.1038/sj.gt.3302039
|
[63]
|
Kumar, V.V., Singh, R.S. and Chaudhuri, A. (2003) Cationic transfection lipids in gene therapy: successes, setbacks, challenges and promises. Current Medicinal Chemistry, 10, 1297-1306. doi:10.2174/0929867033457458
|
[64]
|
Davis, M.E. (2002) Nonviral gene delivery systems. Biotechnol, 13,128-131.
|
[65]
|
Lungwitz, U., Breunig, M., Blunk, T. and Go¨pferich, A. (2005) Polyethylenimine-based nonviral gene delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 60, 247-266. doi:10.1016/j.ejpb.2004.11.011
|
[66]
|
Suzuki, K., Murtuza, B., Smolenski, R.T., Sammut, I.A., Suzuki, N., Kaneda, Y., et al. (2001) Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor expressing skeletal
myoblasts. Circulation, 104, I207-12. doi:10.1161/hc37t1.094524
|
[67]
|
Law, P.K. and Law, D.M. (2011) Human myoblast genome therapies and devices in regenerative medicine. Recent Patents on Regenerative Medicine, 1, 88-117.
|
[68]
|
Clinton, H.R. and Obama, B. (2006) Making patient safety the centerpiece of medical liability reform. The New England Journal of Medicine, 354, 2205-2208. doi:10.1056/NEJMp068100
|
[69]
|
Lunde, K., Solheim, S., Aakhus, S., Arnesen, H., Abdelnoor, M., Egeland T. et al. (2006) Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. The New England Journal of Medicine, 355, 1199-1209. doi:10.1056/NEJMoa055706
|
[70]
|
Schachinger, V., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., Holschermann, H. et al. (2006) Intracoronary bone marrow–derived progenitor cells in acute myocardial infarction. The New England Journal of Medicine, 355, 1210-1221.
|
[71]
|
Assmus, B., Honold, J., Schachinger, V., Britten, M.B., Fischer-Rasokat, U. and Lehmann, R., (2006) Transcoronary transplantation of progenitor cells after myocardial infarction. The New England Journal of Medicine, 355, 1222-1232. doi:10.1056/NEJMoa051779
|